Contributions of TriumphThad

Contributions by TriumphThad, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 1,788 edits includes activity predating the current log.

1. 02:26, 7 May 2026 (diff | hist) Counterfeit peptide 5,488 ±0 m add the note on how to request a batch record rather than a certificate
2. 09:55, 25 Mar 2026 (diff | hist) Talk:TRIUMPH trial programme 400 +132 /* Quoting phase 2 figures */ new section
3. 19:10, 20 Mar 2026 (diff | hist) Cagrilintide 4,256 ±0 ce
4. 03:49, 14 Mar 2026 (diff | hist) Zhuhai Kerui Biotechnology 14,711 +220 add category for suppliers in China
5. 08:33, 5 Aug 2025 (diff | hist) TRIUMPH trial programme 4,549 ±0 m expand §What phase 3 is designed to address
6. 14:43, 30 Jan 2025 (diff | hist) TRIUMPH trial programme 3,495 +99 m state the non-inferiority margin, since the design was non-inferiority
7. 06:18, 11 Jan 2025 (diff | hist) Melanotan II 2,703 +192 add the stability data with the storage condition it was measured at
8. 14:45, 19 Nov 2024 (diff | hist) Placebo-adjusted effect 2,853 +696 fix a dangling clause
9. 04:42, 17 Nov 2024 (diff | hist) Intention-to-treat analysis 3,316 +625 add the trial acronym expansion at first use
10. 17:03, 6 Nov 2024 (diff | hist) GLP-1 receptor agonist 6,539 +232 rm the comparison to a compound with no published head-to-head data
11. 03:35, 26 Oct 2024 (diff | hist) SURPASS trial programme 2,611 ±0 give the absolute risk difference alongside the relative one
12. 22:53, 17 Oct 2024 (diff | hist) Number needed to treat 1,750 +628 expand §Number needed to harm
13. 23:12, 17 Sep 2024 (diff | hist) Timeline of incretin therapeutics 2,352 +166 rm a duplicated category
14. 21:47, 20 Aug 2024 (diff | hist) SELECT trial 1,788 +599 give the absolute risk difference alongside the relative one